| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 09/26/2023 | KalVista Pharmaceuticals, Inc. | KALV | Grant | Stock Option (right to buy) | 10k | $10.08 | $100.8k | | 09/26/2023 |
| 10/13/2022 | KalVista Pharmaceuticals, Inc. | KALV | Grant | Employee Stock Option (right to buy) | 10k | $4.53 | $45.3k | | 10/13/2022 |
| 09/30/2021 | KalVista Pharmaceuticals, Inc. | KALV | Grant | Director Stock Option (Right to Buy) | 10k | $17.45 | $174.5k | | 09/30/2021 |
| 10/30/2020 | KalVista Pharmaceuticals, Inc. | KALV | Purchase | Common Stock | 68.3k | $17.17 | $1.2M | By Vivo Opportunity Fund, L.P. | 10/30/2020 |
| 10/30/2020 | KalVista Pharmaceuticals, Inc. | KALV | Purchase | Common Stock | 47.4k | $17.34 | $822.3k | By Vivo Opportunity Fund, L.P. | 10/30/2020 |
| 10/01/2020 | KalVista Pharmaceuticals, Inc. | KALV | Grant | Director Stock Option (right to buy) | 7k | $12.88 | $90.2k | | 10/01/2020 |
| 10/02/2019 | KalVista Pharmaceuticals, Inc. | KALV | Grant | Director Stock Option (Right to Buy) | 7k | $11.21 | $78.5k | | 10/02/2019 |
| 07/29/2019 | KalVista Pharmaceuticals, Inc. | KALV | Purchase | Common Stock | 24.7k | $17.13 | $423.7k | By Vivo Opportunity Fund, L.P. | 07/26/2019 |
| 07/29/2019 | KalVista Pharmaceuticals, Inc. | KALV | Purchase | Common Stock | 5.1k | $17.13 | $88k | By Vivo Capital Fund IX, L.P. | 07/26/2019 |
| 07/26/2019 | KalVista Pharmaceuticals, Inc. | KALV | Purchase | Common Stock | 21.9k | $16.83 | $369.3k | By Vivo Opportunity Fund, L.P. | 07/26/2019 |
| 07/26/2019 | KalVista Pharmaceuticals, Inc. | KALV | Purchase | Common Stock | 4.6k | $16.83 | $76.7k | By Vivo Capital Fund IX, L.P. | 07/26/2019 |
| 07/19/2019 | KalVista Pharmaceuticals, Inc. | KALV | Purchase | Common Stock | 10.3k | $17.68 | $182.5k | By Vivo Capital Fund IX, L.P. | 07/17/2019 |
| 07/19/2019 | KalVista Pharmaceuticals, Inc. | KALV | Purchase | Common Stock | 49.7k | $17.84 | $886.1k | By Vivo Opportunity Fund, L.P. | 07/17/2019 |
| 07/17/2019 | KalVista Pharmaceuticals, Inc. | KALV | Purchase | Common Stock | 1.1k | $16.97 | $18k | By Vivo Opportunity Fund, L.P. | 07/17/2019 |
| 07/17/2019 | KalVista Pharmaceuticals, Inc. | KALV | Purchase | Common Stock | 220 | $16.93 | $3.7k | By Vivo Capital Fund IX, L.P. | 07/17/2019 |
| 10/03/2018 | KalVista Pharmaceuticals, Inc. | KALV | Grant | Director Stock Option (Right to Buy) | 7k | $22.65 | $158.6k | | 10/03/2018 |
| 09/10/2018 | KalVista Pharmaceuticals, Inc. | KALV | Purchase | Common Stock | 1.1M | $17.00 | $18M | See Footnotes | 09/10/2018 |
| 05/01/2018 | Biohaven Pharmaceutical Holding Co Ltd. | BHVN | Grant | Stock Option (Right to Buy) | 18k | $28.76 | $517.7k | | 05/01/2018 |
| 03/14/2018 | Biohaven Pharmaceutical Holding Co Ltd. | BHVN | Grant | Common Shares | 72.7k | $27.50 | $2M | See footnote | 03/14/2018 |
| 01/29/2018 | VYNE Therapeutics Inc. | MNLO | Conversion | Series C Preferred Stock | 341.8k | $0.00 | $0 | By Vivo Capital Surplus Fund III, L.P. | 01/25/2018 |
| 01/29/2018 | VYNE Therapeutics Inc. | MNLO | Conversion | Series C Preferred Stock | 2.5M | $0.00 | $0 | By Vivo Capital Fund VIII, L.P. | 01/25/2018 |
| 01/29/2018 | VYNE Therapeutics Inc. | MNLO | Conversion | Series B Preferred Stock | 874.8k | $0.00 | $0 | By Vivo Capital Surplus Fund III, L.P. | 01/25/2018 |
| 01/29/2018 | VYNE Therapeutics Inc. | MNLO | Conversion | Series B Preferred Stock | 6.3M | $0.00 | $0 | By Vivo Capital Fund VIII, L.P. | 01/25/2018 |
| 01/29/2018 | VYNE Therapeutics Inc. | MNLO | Conversion | Common Stock | 126.7k | $0.00 | $0 | By Vivo Capital Surplus Fund III, L.P. | 01/25/2018 |
| 01/29/2018 | VYNE Therapeutics Inc. | MNLO | Conversion | Common Stock | 917.6k | $0.00 | $0 | By Vivo Capital Fund VIII, L.P. | 01/25/2018 |
| 01/29/2018 | VYNE Therapeutics Inc. | MNLO | Conversion | Common Stock | 324.3k | $0.00 | $0 | By Vivo Capital Surplus Fund III, L.P. | 01/25/2018 |
| 01/29/2018 | VYNE Therapeutics Inc. | MNLO | Conversion | Common Stock | 2.3M | $0.00 | $0 | By Vivo Capital Fund VIII, L.P. | 01/25/2018 |
| 01/25/2018 | VYNE Therapeutics Inc. | MNLO | Purchase | Common Stock | 35.7k | $17.00 | $606.7k | By Vivo Capital Surplus Fund III, L.P. | 01/25/2018 |
| 01/25/2018 | VYNE Therapeutics Inc. | MNLO | Purchase | Common Stock | 258.4k | $17.00 | $4.4M | By Vivo Capital Fund VIII, L.P. | 01/25/2018 |
| 05/09/2017 | Biohaven Pharmaceutical Holding Co Ltd. | BHVN | Conversion | Common Shares | 1.5M | $0.00 | $0 | See footnote | 05/09/2017 |
| 05/09/2017 | Biohaven Pharmaceutical Holding Co Ltd. | BHVN | Purchase | Common Shares | 470k | $17.00 | $8M | See footnote | 05/09/2017 |
| 05/09/2017 | Biohaven Pharmaceutical Holding Co Ltd. | BHVN | Conversion | Series A Preferred Shares | 1.5M | $0.00 | $0 | See footnote | 05/09/2017 |
| 03/23/2017 | KalVista Pharmaceuticals, Inc. | KALV | Grant | Director Stock Option (Right to Buy) | 12k | $7.88 | $94.6k | | 03/23/2017 |